SCHEMBL20915664

SCHEMBL20915664

COc1nc(O)c(C(=O)Nc2ccc(-c3[nH]nnc3C)cc2)c(=O)[nH]1

nearest known ligand 0.67

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
XDH P47989 18/20 0.67
SLC22A12 Q96S37 5/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20929217 0.86 XDH (0.70) XDHSLC22A12
SCHEMBL20915726 0.84 XDH (0.67) XDHSLC22A12
SCHEMBL22364252 0.81 XDH (0.67) XDHSLC22A12
SCHEMBL10733888 0.79 XDH (0.65) XDHSLC22A12
SCHEMBL20179427 0.75 XDH (0.61) XDHSLC22A12
SCHEMBL20179455 0.72 XDH (0.60) XDHSLC22A12
SCHEMBL20915704 0.65 XDH (0.69) XDHSLC22A12
SCHEMBL20915739 0.65 XDH (0.69) XDHSLC22A12
SCHEMBL20915847 0.65 XDH (0.69) XDHSLC22A12
SCHEMBL22353091 0.65 XDH (0.72) XDHSLC22A12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3481819-B1 COMPOUNDS AND THEIR USE FOR REDUCING URIC ACID LEVELS ACQUIST LLC (US) 2022-06-01 EP disclosed
EP-3481819-B1 COMPOUNDS AND THEIR USE FOR REDUCING URIC ACID LEVELS ACQUIST LLC (US) 2022-06-01 EP disclosed
US-20220024900-A1 Compounds and Their Use for Reducing Uric Acid Levels ACQUIST LLC (US) 2022-01-27 US disclosed
US-20220024900-A1 Compounds and Their Use for Reducing Uric Acid Levels ACQUIST LLC (US) 2022-01-27 US disclosed
CN-109476642-B Compounds and their use for reducing uric acid levels 阿奎斯特有限责任公司 2022-01-25 CN disclosed
US-11168075-B2 Compounds and their use for reducing uric acid levels ACQUIST LLC (US) 2021-11-09 US disclosed
US-11168075-B2 Compounds and their use for reducing uric acid levels ACQUIST LLC (US) 2021-11-09 US disclosed
US-20210236495-A1 Compounds and Their Use for Reducing Uric Acid Levels ACQUIST LLC (US) 2021-08-05 US disclosed
US-20210236495-A1 Compounds and Their Use for Reducing Uric Acid Levels ACQUIST LLC (US) 2021-08-05 US disclosed
US-11020397-B2 Compounds and their use for reducing uric acid levels ACQUIST LLC (US) 2021-06-01 US disclosed
US-10759784-B2 Compounds and their use for reducing uric acid levels ACQUIST LLC (US) 2020-09-01 US disclosed
US-10759784-B2 Compounds and their use for reducing uric acid levels ACQUIST LLC (US) 2020-09-01 US disclosed
US-20200268757-A1 Compounds and Their Use for Reducing Uric Acid Levels ACQUIST LLC (US) 2020-08-27 US disclosed
US-20200268757-A1 Compounds and Their Use for Reducing Uric Acid Levels ACQUIST LLC (US) 2020-08-27 US disclosed
US-20200197393-A9 Compounds and Their Use for Reducing Uric Acid Levels ACQUIST LLC 2020-06-25 US disclosed
US-20200197393-A9 Compounds and Their Use for Reducing Uric Acid Levels ACQUIST LLC 2020-06-25 US disclosed
US-10688095-B2 Compounds and their use for reducing uric acid levels ACQUIST LLC (US) 2020-06-23 US disclosed
US-10688095-B2 Compounds and their use for reducing uric acid levels ACQUIST LLC (US) 2020-06-23 US disclosed
US-20190117654-A1 Compounds and Their Use for Reducing Uric Acid Levels ACQUIST LLC (US) 2019-04-25 US disclosed
US-20190117654-A1 Compounds and Their Use for Reducing Uric Acid Levels ACQUIST LLC (US) 2019-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220024900-A1 Compounds and Their Use for Reducing Uric Acid Levels XDH, OAT, PON1 XDH 1/4885SLC22A12 327/4885
US-11168075-B2 Compounds and their use for reducing uric acid levels XDH, OAT, PON1 XDH 1/4885SLC22A12 327/4885
US-10688095-B2 Compounds and their use for reducing uric acid levels XDH, OAT, UGT2B7 XDH 1/4885SLC22A12 437/4885
US-20210236495-A1 Compounds and Their Use for Reducing Uric Acid Levels XDH, OAT, URB2 XDH 1/4885SLC22A12 372/4885
US-20200268757-A1 Compounds and Their Use for Reducing Uric Acid Levels XDH, OAT, URB2 XDH 1/4885SLC22A12 372/4885
US-10759784-B2 Compounds and their use for reducing uric acid levels XDH, OAT, PON1 XDH 1/4885SLC22A12 327/4885
US-11020397-B2 Compounds and their use for reducing uric acid levels XDH, OAT, UGT2B7 XDH 1/4885SLC22A12 437/4885
US-20200197393-A9 Compounds and Their Use for Reducing Uric Acid Levels XDH, OAT, URB2 XDH 1/4885SLC22A12 372/4885
US-20190117654-A1 Compounds and Their Use for Reducing Uric Acid Levels XDH, OAT, URB2 XDH 1/4885SLC22A12 372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.